[1] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
[2] |
WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong.
Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
|
[3] |
WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken .
Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
|
[4] |
LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui.
Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
|
[5] |
CHEN Yining, XIAO Yun, HAN Xiaoyu, HUANG Lulu, MA Jingsheng, XIONG Hanbin, FU Yu, WANG Baolin, GUO Xiaohui, ZHONG Lin, AO Jiangen, HE Jiake.
Diagnosis and individualized drug therapy for the rejection with hyperglycemia after liver Transplantation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 550-555.
|
[6] |
HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu.
Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
|
[7] |
ZHAO Shifeng, SONG Xiangming, YAO Jianping.
Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
|
[8] |
SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju.
Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
|
[9] |
DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo.
Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
|
[10] |
CAI Jing, PAN Binjing, LIU Jingfang.
Research progress on the relationship between hypoglycemic drugs and sarcopenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
|
[11] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
[12] |
MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling.
Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
|
[13] |
WEI Feng, HE Yang, FAN Zhiqiang, LIU Shikun, OUYANG Linqi.
Inhibitory effect of flufenidone on TGF-β1/Smads pathway in hepatocytes of rats with diethylnitrosamine (DEN)-induced liver injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 739-746.
|
[14] |
LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying.
Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
|
[15] |
LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei.
Research progress of virus-mediated gene therapy in type 2 diabetes mellitu
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
|